NCT00275171View on ClinicalTrials.gov

rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

April 30, 2009

Study Completion Date

September 30, 2009

Conditions
Nodular Goiter
Interventions
DRUG

Recombinant human thyrotropin (Thyrogen)

0.1 mg rhTSH administered intramuscularly

DRUG

recombinant human TSH

0.1 mg rhTSH administered intramuscularly

OTHER

isotonic saline = placebo

0.1 mg isotonic saline injected intramuscularly

Trial Locations (1)

5000

Odense University Hospital, Odense

All Listed Sponsors
lead

Steen Bonnema

OTHER

NCT00275171 - rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter | Biotech Hunter | Biotech Hunter